Heron Therapeutics, Inc. (NASDAQ:HRTX) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

HRTX has been the topic of a number of other reports. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a research note on Friday, May 12th. Zacks Investment Research lowered shares of Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 9th. Cowen and Company set a $40.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, August 3rd. Aegis reiterated a “buy” rating and issued a $33.00 price objective on shares of Heron Therapeutics in a report on Tuesday, July 18th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $26.00 price objective on shares of Heron Therapeutics in a report on Friday, July 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company. Heron Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $31.00.

Heron Therapeutics (NASDAQ HRTX) opened at 16.40 on Friday. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $20.85. The stock has a 50 day moving average of $15.77 and a 200 day moving average of $14.76.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.10. The company had revenue of $8.51 million during the quarter, compared to analyst estimates of $4.53 million. On average, analysts expect that Heron Therapeutics will post ($3.51) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Heron Therapeutics, Inc. (HRTX) Stock Rating Upgraded by BidaskClub” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/28/heron-therapeutics-inc-hrtx-stock-rating-upgraded-by-bidaskclub.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc raised its position in shares of Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,098 shares during the period. Venturi Wealth Management LLC purchased a new position in Heron Therapeutics during the first quarter valued at about $161,000. Quantbot Technologies LP raised its position in Heron Therapeutics by 2,619.6% in the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 12,024 shares during the last quarter. Old West Investment Management LLC purchased a new position in Heron Therapeutics during the first quarter valued at about $206,000. Finally, HighTower Advisors LLC raised its position in Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 1,700 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.